1. Home
  2. AMH vs INCY Comparison

AMH vs INCY Comparison

Compare AMH & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Homes 4 Rent of Beneficial Interest

AMH

American Homes 4 Rent of Beneficial Interest

HOLD

Current Price

$30.96

Market Cap

11.8B

Sector

Real Estate

ML Signal

HOLD

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$102.46

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMH
INCY
Founded
2012
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Commercial Physical & Biological Resarch
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.8B
17.0B
IPO Year
2013
1993

Fundamental Metrics

Financial Performance
Metric
AMH
INCY
Price
$30.96
$102.46
Analyst Decision
Buy
Buy
Analyst Count
15
20
Target Price
$38.20
$90.71
AVG Volume (30 Days)
2.5M
2.0M
Earning Date
10-29-2025
10-28-2025
Dividend Yield
3.89%
N/A
EPS Growth
23.05
3878.02
EPS
1.18
5.90
Revenue
$1,831,836,000.00
$4,813,105,000.00
Revenue This Year
$8.29
$19.59
Revenue Next Year
$4.11
$10.88
P/E Ratio
$26.14
$17.37
Revenue Growth
7.71
18.09
52 Week Low
$30.63
$53.56
52 Week High
$39.49
$109.28

Technical Indicators

Market Signals
Indicator
AMH
INCY
Relative Strength Index (RSI) 34.23 54.83
Support Level $31.80 $100.55
Resistance Level $32.73 $107.61
Average True Range (ATR) 0.49 2.94
MACD -0.09 -0.98
Stochastic Oscillator 9.31 45.19

Price Performance

Historical Comparison
AMH
INCY

About AMH American Homes 4 Rent of Beneficial Interest

American Homes 4 Rent is a real estate investment trust focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's geographical markets include Dallas, Texas; Indianapolis, Indiana; Atlanta, Georgia; and Charlotte, North Carolina in terms of the number of properties in each.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: